Amneal Pharmaceuticals (NYSE:AMRX) Lifted to Hold at Zacks Investment Research

Amneal Pharmaceuticals (NYSE:AMRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports.

According to Zacks, “Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories Inc., is based in New Jersey, United States. “

AMRX has been the topic of several other reports. Svb Leerink downgraded shares of Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. ValuEngine downgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. Piper Jaffray Companies lifted their price objective on shares of Amneal Pharmaceuticals from $4.00 to $7.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Royal Bank of Canada lifted their price objective on shares of Amneal Pharmaceuticals from $3.00 to $4.00 and gave the company a “sector perform” rating in a report on Thursday, January 2nd. Finally, Raymond James downgraded shares of Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company’s stock. Amneal Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $6.30.

AMRX stock traded down $0.05 during mid-day trading on Tuesday, hitting $4.68. 1,606,919 shares of the company were exchanged, compared to its average volume of 1,747,554. The company has a debt-to-equity ratio of 6.91, a quick ratio of 1.50 and a current ratio of 2.25. The firm has a market cap of $1.41 billion, a P/E ratio of 4.93, a P/E/G ratio of 0.66 and a beta of 1.61. The firm’s 50 day simple moving average is $4.14 and its 200 day simple moving average is $3.75. Amneal Pharmaceuticals has a 1-year low of $2.27 and a 1-year high of $15.14.

Amneal Pharmaceuticals (NYSE:AMRX) last announced its earnings results on Wednesday, November 6th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.09). The company had revenue of $378.30 million for the quarter, compared to analyst estimates of $403.90 million. Amneal Pharmaceuticals had a positive return on equity of 23.17% and a negative net margin of 19.61%. The business’s quarterly revenue was down 20.6% on a year-over-year basis. During the same quarter last year, the business posted $0.28 earnings per share. On average, equities research analysts predict that Amneal Pharmaceuticals will post 0.26 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of AMRX. Swiss National Bank increased its holdings in Amneal Pharmaceuticals by 2.1% during the second quarter. Swiss National Bank now owns 171,200 shares of the company’s stock worth $1,228,000 after buying an additional 3,600 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Amneal Pharmaceuticals by 110.7% during the second quarter. JPMorgan Chase & Co. now owns 50,036 shares of the company’s stock worth $355,000 after buying an additional 26,285 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Amneal Pharmaceuticals by 96.3% during the second quarter. Acadian Asset Management LLC now owns 45,000 shares of the company’s stock worth $323,000 after buying an additional 22,073 shares during the last quarter. Bank of Montreal Can increased its holdings in Amneal Pharmaceuticals by 87.5% during the second quarter. Bank of Montreal Can now owns 8,475 shares of the company’s stock worth $60,000 after buying an additional 3,954 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Amneal Pharmaceuticals by 4.9% during the second quarter. Charles Schwab Investment Management Inc. now owns 705,657 shares of the company’s stock worth $5,060,000 after buying an additional 33,072 shares during the last quarter. Institutional investors and hedge funds own 35.80% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

See Also: Stock Portfolio Tracker

Get a free copy of the Zacks research report on Amneal Pharmaceuticals (AMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.